Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bosutinib - Pfizer

Drug Profile

Bosutinib - Pfizer

Alternative Names: Bosulif; PF-05208763; PF-5208763; SKI-606

Latest Information Update: 29 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wyeth
  • Developer Avillion; Kyoto University; Massachusetts General Hospital; Pfizer; University of Texas M. D. Anderson Cancer Center
  • Class Aniline compounds; Antineoplastics; Nitriles; Piperazines; Quinolines; Small molecules; Urologics
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Src-Family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia
  • Phase II Glioblastoma
  • Phase I/II Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I Amyotrophic lateral sclerosis
  • Discontinued Autosomal dominant polycystic kidney disease; Breast cancer; Solid tumours

Most Recent Events

  • 29 Aug 2019 Safety and efficacy data from a phase IV trial for Chronic myeloid leukaemia were presented at the 24th Congress of the European Hematology Association (EHA-2019)
  • 31 May 2019 Adverse events data from the phase-III BFORE trial in Chronic myeloid leukaemia presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)
  • 29 Mar 2019 Phase-I clinical trials in Amyotrophic lateral sclerosis in Japan (PO) (UMIN000036295)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top